US-EU Index Rebalances / Quantitative Researcher, ORTEX

Dimitris Ioannidis

Index Rebalance professional of US, EU and Global Indices. Specialized in shareholder structure and index free float calculation, SPACs, quarterly rebalance predictions of US-EU indices and cross-index implications of corporate actions such as M&A's, Spin-offs and IPOs.

All forecasts and calculations are estimates derived from a combination of public sources considered reliable. These sources include, but are not limited to, exchange and regulatory filings, company announcements, and ETFs. While best efforts are made to maximize accuracy, estimates and predictions are subject to uncertainty.

No index data are used.

US-EU Index Rebalances / Quantitative Researcher

Medline Aims for a $5 Billion IPO as America’s Largest Privately Held Medical Supplier

Medline Inc. (MDLN): Hospital Product & Supply Chain Company Sets Terms on Mega IPO, $5b+ Cash Raise

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Index Rebalance

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medline-inc" target="_blank" data-smartkarma-citation="entities:45954:1" rel="noopener">Medline (MDLN US)</a> goes public on 17 December on Nasdaq with an estimated market cap of $40bn, 27% lower than the consensus of $55bn.</li>
<li>Inclusion in US indices is expected in March 2026, as the security meets US eligibility criteria before the lock-up expiry.</li>
<li>Inclusion in Global indices is expected in May and June 2026 with a potential delay to August due to low float cap.</li>
</ul>



Medline (MDLN US) goes public on 17 December on Nasdaq with an estimated market cap of $40bn, 27% lower than the consensus of $55bn.
Inclusion in US indices is expected in March 2026, as the security meets US eligibility criteria before the lock-up expiry.
Inclusion in Global indices is expected in May and June 2026 with a potential delay to August due to low float cap.


Medline (MDLN US): Global & US Index Inclusion; Overestimated Valuation?